Stock Analysis
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis
Mirum Pharmaceuticals, Inc. (MIRM) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Mirum Pharmaceuticals, Inc. (MIRM) currently has an AIQ Score of 53/100, indicating a neutral setup. Value is the strongest factor at 57/100. Risk is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
MIRM at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $93.99 |
| AIQ Score | 53/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $6.16B |
| P/E Ratio (TTM) | -6.17 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.62 |
| Revenue (Q3 FY2026) | $185.72M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.07 |
| Volume | 331.06K |
| 52-week range | $63.23-$130.00 |
| RSI 14 | 59.88 |
| 50-Day SMA | $88.79 |
| 200-Day SMA | $98.41 |
| Analyst Price Target | $156.89 |
| Next Earnings | Feb 24, 2027 |
MIRMMirum Pharmaceuticals, Inc.
Healthcare / Biotechnology
Low Priority
In Line With Peers
Latest quote
- Momentum54
- Value57
- Quality52
- Risk resilience51
- Sentiment—
MIRM Stock Analysis Summary
Mirum Pharmaceuticals, Inc. (MIRM) currently has an AIQ Score of 53/100, indicating a neutral setup. Value is the strongest factor at 57/100. Risk resilience is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, MIRM has AIQ Score of 53/100 with Value base of 57/100 and fading Risk resilience at 51/100. Wait for component alignment before adding exposure.
Healthcare · 0.71% stock move · MIRM classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is MIRM Bullish or Bearish Right Now?
MIRM currently has a neutral overall setup. Value is the strongest factor at 57/100, while Risk Resilience is weakest at 51/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Price is +5.86% above its 50-day SMA.
- - Analyst target implies +66.92% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (33 vs 4).
- - Price is -4.49% below its 200-day SMA.
Current Consensus
MIRM's Technical Analysis Consensus is currently Strong Buy, with 33 buy, 9 neutral, and 4 sell votes. MIRM's 14-day RSI is 59.88, which places the stock in a constructive momentum range. MIRM's beta is 1.07, indicating market sensitivity broadly in line with the market.
What Changed in MIRM?
The largest recent change in MIRM is Momentum moving up by 8.0 points over the available 7-day comparison window. Value remains the strongest visible factor.
What Would Change the MIRM Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
MIRM Decision Framework
Public evidence layers, setup checks, and risk context for Mirum Pharmaceuticals, Inc..
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis
Mirum Pharmaceuticals, Inc. has an AIQ Score of 53/100 in a Neutral regime. Value is strongest at 57/100. Beta is 1.07, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | MIRM is in a Neutral AIQ regime with score 53/100. |
| Signal Conflict | The primary conflict is that value leads at 57/100 while risk lags at 51/100. |
| Factor Evidence | Momentum 54/100 · Value 57/100 · Quality 52/100 · Risk 51/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 57/100.
Momentum is 54/100 and RSI (14) is 59.9.
MIRM is in a Neutral regime at 53/100.
Risk factor is 51/100 with beta 1.07 and annual volatility 48.6%.
Current conflict: value leads at 57/100 while risk lags at 51/100.
MIRM Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
MIRM Fundamentals
MIRM valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
MIRM Technical Analysis
MIRM technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
MIRM Stock Catalysts
Track MIRM earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
MIRM Dividend Analysis
MIRM dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
MIRM Financial Data
MIRM revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
MIRM Risk Analysis
MIRM volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
MIRM Stock News
MIRM stock news, market tone, recent headlines, and catalyst context.
MIRM vs Biotechnology Peers
Current peer cohort: MIRM · MLYS · NAMS · NBIX · NKTR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| MIRM Current stock | 53/100 | 57/100 | 54/100 | 51/100 | 0.79 | 48.60% | Current |
| MLYS Mineralys Therapeutics, Inc. | 33/100 | — | 23/100 | 35/100 | -1.48 | 61.66% | MIRM vs MLYS |
| NAMS NewAmsterdam Pharma Company N.V. | 41/100 | 42/100 | 22/100 | 48/100 | -0.91 | 53.82% | MIRM vs NAMS |
| NBIX Neurocrine Biosciences, Inc. | 74/100 | 77/100 | 70/100 | 69/100 | 0.49 | 35.22% | MIRM vs NBIX |
| NKTR Nektar Therapeutics | 39/100 | 47/100 | 25/100 | 41/100 | -0.11 | 84.03% | MIRM vs NKTR |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for MIRM: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching MIRM
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for MIRM
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
MIRM Stock FAQ
What is MIRM stock price today?
Mirum Pharmaceuticals, Inc.'s current stock price is $93.99. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is MIRM bullish or bearish right now?
MIRM's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is MIRM's market cap?
MIRM's market cap is $6.16B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is MIRM's current P/E ratio?
MIRM's current P/E ratio is -6.17 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is MIRM's RSI?
MIRM's 14-day RSI is 59.88 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is MIRM above its 50-day and 200-day moving averages?
MIRM is 5.86% from its 50-day SMA and -4.49% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is MIRM's next earnings date?
MIRM's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does MIRM pay a dividend?
MIRM's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.